| |
• The new high‑performance sterile glass cartridge is engineered for stability of complex biologics across their shelf life;
• It complements EVERIC® pure vials and syriQ BioPure® syringes, enabling an unbiased container choice across the drug lifecycle;
• Commercial launch is planned for year‑end at CPHI Milan 2026; samples are already available.
Featuring enhanced chemical resistance and an improved extractables and leachables profile, it is designed to meet the demanding requirements of modern biotech medicines.
“As therapies become increasingly complex and sensitive, we are investing in high-quality primary packaging that safeguards drug stability, supports comfortable administration, and scales with our customers’ pipelines,” says Andreas Reisse, CEO of SCHOTT Pharma. “The optimized cartridge expands our high‑value solutions portfolio for biological drugs and empowers pharmaceutical companies to select the right container vial, syringe, or cartridge based on the specific molecules' needs and lifecycle of each therapy.”
Engineered for complex biologics such as monoclonal antibodies, fusion proteins, and other sensitive molecules, as well as fertility treatments and therapies for growth hormone deficiencies, cartriQ® BioPure addresses key challenges for pharmaceutical companies. These include long‑term drug stability with reduced risk of leachable effects, low levels of free silicone, and compatibility with drug-delivery devices that enable safe and reliable administration. By complementing EVERIC® pure vials and syriQ BioPure® glass syringes, the advanced glass cartridge provides pharmaceutical companies with a comprehensive container choice from early development through commercial supply.
A new benchmark for sensitive biologics
cartriQ® BioPure combines SCHOTT Pharma’s long-standing materials expertise with targeted process innovations to deliver a high-performance glass cartridge platform for sensitive biologics. It is manufactured from enhanced FIOLAX® Pro glass tubing, offering exceptional chemical quality and an improved extractables and leachables profile. By applying strict release criteria for sodium and aluminum, the cartridge performs significantly below ISO maximum limits for hydrolytic resistance and goes beyond evolving regulatory expectations, including the current USP <660> draft. This level of control supports robust stability profiles for sensitive biologics, both today and in the future.
To further minimize drug container interaction, the sterile glass cartridge employs baked‑on silicone technology, achieving low and well-controlled silicone levels that are verified through rigorous release testing. Coated elastomers used for plunger stoppers and combi-seals, along with improved surface durability and optimized residual seal force, collectively preserve drug integrity from fill‑and-finish through to patient delivery. Tight body tolerances enable accurate dosing an essential requirement for therapies with narrow therapeutic windows while enhanced mechanical strength significantly reduces breakage risk during handling and administration steps.
cartriQ® BioPure will be available in 3 ml and 5 ml for use with pens and autoinjectors to facilitate self-administration. While the commercial launch is planned for the end of the year at CPHI Milan 2026, samples of this glass cartridge are already available.
About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma (schott-pharma.com) designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment.
|
lea.kaiser[.]schott.com 
